# Re-evaluation Task: LUN-009

## Context
- **Case ID**: LUN-009
- **Cancer type**: Non-small cell lung cancer (NSCLC) — EGFR exon 20 insertion mutation
- **Stage**: Stage IVA
- **Molecular profile**: EGFR exon 20 insertion mutation
- **Report file**: experiment_reports\LUN-009_report.json
- **Current score**: 87/100
- **Gap analysis (local GPU)**: The missing intent data for Amivantamab Monotherapy (Post-Platinum) and Zipalertinib (CLN-081) Monotherapy are crucial gaps that need to be filled as they provide essential information on the efficacy and safety of these treatments in post-platinum settings, which is a critical area of research. Filling these gaps will improve the score by providing more comprehensive insights into the treatment outcomes of patients with non-small cell lung cancer (NSCLC) who have received platinum-based chemotherapy, allowing for more informed decision-making and potential improvements in patient care.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  14/25  |  56.0% |
| clinical_relevance                  |   9/10  |  90.0% |
| rating_calibration                  |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (56.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\LUN-009_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Non-small cell lung cancer (NSCLC) — EGFR exon 20 insertion mutation",
    "stage": "Stage IVA",
    "molecular_profile": [
      "EGFR exon 20 insertion mutation"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Amivantamab + Carboplatin + Pemetrexed (First-Line PAPILLON Regimen)",
      "category": "Approved Targeted Therapy + Chemotherapy",
      "composite_rating": 8.8,
      "rating_breakdown": {
        "evidence_level": {
          "score": 10,
          "rationale": "Phase 3 RCT (PAPILLON, NCT04538664) published in NEJM 2023. Randomized 308 patients. Definitive evidence supporting first-line use. NCCN Category 1 recommendation"
        },
        "survival_benefit": {
          "score": 8,
          "rationale": "Median PFS 11.4 months vs 6.7 months (HR 0.40, p<0.001). ORR 73% vs 47%. 18-month PFS 31% vs 3%. Interim OS HR 0.67 (not yet significant). Transforms outcomes in this historically challenging subtype"
        },
        "accessibility": {
          "score": 10,
          "rationale": "FDA approved March 2024 for first-line EGFR ex20ins NSCLC. Subcutaneous formulation (Rybrevant Faspro) also approved, reducing infusion time from hours to minutes. Widely available globally"
        },
        "safety_profile": {
          "score": 6,
          "rationale": "Infusion-related reactions (66% IV, reduced with SC), rash (86%), paronychia, hypoalbuminemia. Grade 3+ AEs 75%. Venous thromboembolism risk. Manageable but requires monitoring. SC formulation improves tolerability"
        },
        "biomarker_match": {
          "score": 10,
          "rationale": "Specifically designed for EGFR exon 20 insertion mutations. Patient's exact molecular profile. EGFR-MET bispecific antibody directly targets the driver mutation"
        }
      },
      "mechanism_of_action": "Amivantamab is a bispecific antibody targeting both EGFR and MET receptors with immune cell-directing activity. It inhibits ligand binding, promotes receptor endocytosis and degradation, and engages macrophages, monocytes, and natural killer cells through its Fc domain. Combined with carboplatin-pemetrexed chemotherapy for synergistic cytotoxic and targeted effect.",
      "key_evidence": {
        "study_name": "PAPILLON Phase 3 (NCT04538664)",
        "journal": "New England Journal of Medicine",
        "year": 2023,
        "sample_size": 308,
        "os_months": {
          "treatment": 0,
          "control": 0,
          "hazard_ratio": 0.67,
          "p_value": 0.11
        },
        "pfs_months": {
          "treatment": 11.4,
          "control": 6.7
        },
        "orr_percent": {
          "treatment": 73,
          "control": 47
        }
      },
      "biomarker_requirements": [
        "EGFR exon 20 insertion mutation"
      ],
      "notable_side_effects": [
        "infusion-related reactions (66% IV; reduced with SC)",
        "rash (86%)",
        "pa
... (truncated — read full file from experiment_reports\LUN-009_report.json)
```
